HAHanna Lianti Afladhia

Hanna Lianti Afladhia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hanna Lianti Afladhia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study

    by Erlina Burhan, Farchan Azzumar, Fira Alyssa Gabriella Sinuraya, Sabarinah Prasetyo, Dwi Gayatri, Iwan Ariawan, Muhammad Ilham Dhiya Rakasiwi, Hanna Lianti Afladhia, Ahmad Fadhil Ilham, Ihya Akbar, et al.

    Background: Vaccination was included in the Indonesian government policy to address Delta and Omicron waves of SAR-CoV-2 infections. This study assesses the effectiveness of inactivated (CoronaVac, BBIBP-Cor) and mRNA vaccines (mRNA-1273, BNT162b2) against COVID-19 regardless of symptoms and fatal COVID-19 (mortality within 30 days after confirmed RT-PCR) during Delta and Omicron period in Jakarta, Indonesia. Methods: This study case-control, test-negative study included all individuals aged over 18 years in Jakarta with complete and consistent SARS-CoV-2 RT-PCR results from 1 June to 31 August 2021 (Delta period) and 1 January to 2 April 2022 (Omicron period), as well as complete vaccination status. This study integrates several public health data from the Jakarta provincial government. From the odds ratio, vaccine effectiveness (VE) was analyzed as the primary outcome using unmatched analysis, matched analysis, and adjustments for other factors. Results: This study includes 982,885 eligible subjects recorded from March 2021 to April 2022. All subjects generally underwent testing 4–9 weeks after their last vaccine dose. The VE of 2-dose inactivated vaccine against SARS-CoV-2 infection during Delta wave was 22.06% (95% CI 20.63–24.54) and the VE against fatal COVID-19 was 78.55% (95% CI 72.91–83.00). A complete primary dose of mRNA vaccine showed VE of 24.81% (95% CI 16.81–32.09) against infection during Omicron wave. Furthermore an additional mRNA booster dose showed VE of 68.82% (95% CI 54.11–78.82) based on unmatched analysis. Conclusion: A complete primary dose of inactivated vaccine provided mild protection against COVID-19 and essential protection against fatal cases during the Delta wave, but offered little to no protection during the Omicron wave. In contrast, the mRNA vaccine, either as primary vaccination, homologous, or heterologous booster regimen, conferred acceptable protection against Omicron. This study recommends real-world vaccination strategies for LMICs with typical vaccine supply constraints.


  • Open Access

    Depression in Patients with Lung Cancer during the COVID-19 Pandemic

    by Hanna Lianti Afladhia, Sita Andarini

    Introduction: The coronavirus disease (COVID-19) pandemic has caused significant disruptions in various aspects of life, leading to psychological distress and an increase in mental health disorders, particularly in vulnerable populations such as lung cancer patients. This study investigated the depression levels among lung cancer patients during the COVID-19 pandemic. Methods: A cross-sectional study was conducted at the Thoracic Oncology Outpatient Clinic of Persahabatan National Respiratory Referral Hospital, Jakarta. Depression levels were evaluated using the Patient Health Questionnaire-9 (PHQ-9) in Indonesian. Sociodemographic and clinical characteristics and COVID-19-related stress factors (such as concerns about treatment delays, access to healthcare, psychological pressure, and interpersonal relationships) were also assessed. Results: Out of 42 patients, 42.9% were found to have depression during the pandemic. Factors significantly associated with depression included being female, having a lower economic status, poor performance status, undergoing chemotherapy, and experiencing higher levels of psychological pressure related to COVID-19. Conclusion: This study highlighted a high prevalence of depression among lung cancer patients during the COVID-19 pandemic. Psychological assessment and interventions are crucial to prevent further deterioration in mental health and quality of life, which could negatively affect patients' prognoses.

  • Open Access

    Risk factors for viral hepatitis in pulmonary tuberculosis patients undergoing treatment: A systematic review and meta-analysis

    by Ahmad F. Ilham, Salsabila R. Andini, Hanna L. Afladhia, Muhammad Id. Rakasiwi, Erlina Burhan

    Liver injury in tuberculosis patients, associated with noncompliance with treatment, is further exacerbated by viral hepatitis, which not only directly harms the liver but also increases susceptibility to drug-induced liver injury. The aim of this study was to analyze the associated risk factors for viral hepatitis in tuberculosis patients. This systematic review and meta-analysis adhere to the PRISMA 2020 statement, and the protocol has been registered with PROSPERO (CRD42023477241). Screening and selection of articles were carried out according to predetermined inclusion and exclusion criteria, utilizing four databases: Embase, Medline, Scopus, and ProQuest. Baseline characteristics and patient-related risk factors from each included study were extracted, followed by a meta-analysis of factors that potentially had significance, with the heterogeneities also being analyzed. Of the 21 included studies out of 6,415 identified records, 12 potential risk factors for hepatitis B and 15 for hepatitis C were subjected to meta-analysis. Some key risk factors included for hepatitis B and C were HIV infection (OR: 3.42; 95%CI: 2.19–5.34 and OR: 6.99; 95%CI: 5.09–9.61, respectively), smoking (OR: 1.55; 95%CI: 1.19–2.02 and OR: 3.06; 95%CI: 1.63–5.75, respectively) and alcohol consumption (OR: 2.38; 95%CI: 1.06–5.37 and OR: 4.32; 95%CI: 2.76–6.78, respectively). Furthermore, meta-analysis indicated that other significant risk factors for hepatitis B and/or C include injecting and non-injecting drug use, multiple sexual partners, tattooing, ear-nose piercing, blood transfusion, dental interventions, homelessness, incarceration, living with prisoners, sexually transmitted diseases, and diabetes mellitus. In conclusion, patients with tuberculosis who have risk factors such as smoking, HIV, or alcohol consumption should be screened for hepatitis B and C to prevent liver injury.